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ABSTRACT
Introduction: People with type 1 diabetes (T1DM)
require insulin therapy to sustain life, and need optimal
glycaemic control to prevent diabetic ketoacidosis and
serious long-term complications. Insulin is generally
administered using multiple daily injections but can also
be delivered using an infusion pump (continuous
subcutaneous insulin infusion), a more costly option
with benefits for some patients. The UK National
Institute for Health and Care Excellence (NICE)
recommend the use of pumps for patients with the
greatest need, citing insufficient evidence to approve
extension to a wider population. Far fewer UK adults use
pumps than in comparable countries. Previous trials of
pump therapy have been small and of short duration
and failed to control for training in insulin adjustment.
This paper describes the protocol for a large
randomised controlled trial comparing pump therapy
with multiple daily injections, where both groups are
provided with high-quality structured education.
Methods and analysis: A multicentre, parallel group,
cluster randomised controlled trial among 280 adults
with T1DM. All participants attended the week-long
dose adjustment for normal eating (DAFNE) structured
education course, and receive either multiple daily
injections or pump therapy for 2 years. The trial
incorporates a detailed mixed-methods psychosocial
evaluation and cost-effectiveness analysis. The primary
outcome will be the change in glycosylated
haemoglobin (HbA1c) at 24 months in those
participants whose baseline HbA1c is at or above 7.5%
(58 mmol/mol). The key secondary outcome will be the
proportion of participants reaching the NICE target of an
HbA1c of 7.5% (58 mmol/mol) or less at 24 months.
Ethics and dissemination: The protocol was
approved by the Research Ethics Committee North
West, Liverpool East and received Medicines and
Healthcare products Regulatory Agency (MHRA) clinical
trials authorisation. Each participating centre gave
National Health Service R&D approval. We shall
disseminate study findings to study participants and
through peer reviewed publications and conference
presentations, including lay user groups.
Trial registration number: ISRCTN 61215213.
INTRODUCTION
People with type 1 diabetes mellitus (T1DM;
around 250 000 individuals in the UK) have
lost the ability to make insulin due to auto-
immune destruction of the insulin secreting
β cells within pancreatic islets. Treatment
with an external source of insulin is essential
and life long. In the short-term insulin pre-
vents diabetic ketoacidosis, a potentially fatal
condition. In the long term, therapy is
designed to keep blood glucose as close to
normal as possible, to prevent microvascular
complications such as retinopathy, neur-
opathy and nephropathy and to reduce the
risk of macrovascular disease.1 A further aim
of treatment is to achieve as good a quality of
life (QoL) as possible, particularly since
appropriate self management of the condi-
tion is challenging and arduous, demanding
the implementation of complex skills.
Insulin is generally administered by intermit-
tent subcutaneous injection with the dose
adjusted according to eating, physical activity
and current blood glucose levels. Traditionally,
insulin was given twice a day, often as pre-
mixed insulin, but such an approach imposes
a rigid lifestyle on patients and makes it difﬁ-
cult to maintain blood glucose levels close to
Strengths and limitations of this study
▪ Multicentre randomised controlled trial.
▪ The first randomised trial comparing insulin
pumps with multiple daily injections, where both
groups have received high-quality structured
education.
▪ Long-term follow-up, with a 24-month primary
outcome.
▪ Comprehensive psychosocial evaluation and
cost-effectiveness analysis.
▪ Blinding of participants is not possible.
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normal. Most individuals require intensive insulin therapy
to maintain tight glycaemic control. This approach and its
integration within ﬂexible lifestyles is promoted in dose
adjustment for normal eating (DAFNE)2 and similar struc-
tured training courses.3 Flexible intensiﬁed insulin
therapy involves the combination of quick-acting insulin
before eating (altered according to the amount of carbo-
hydrate) and long-acting background ‘basal’ insulin to
control blood glucose in between meals. Basal insulin is
generally given twice daily.
The combination is generally referred to as ‘multiple
daily injections’, or MDI. It often involves a total of 5,
even 6 injections a day, frequent checks of blood glucose
from ﬁnger prick samples using a portable meter and
dose adjustment based on the amount of carbohydrate
eaten at each meal. Insulin given subcutaneously cannot
reproduce the physiology of insulin secretion of indivi-
duals without diabetes due to the limitations of insulin
prepared for therapeutic use and its delivery into the sys-
temic rather than the portal circulation. The relatively
slow rate of insulin absorption leads to postprandial
hyperglycaemia and often postabsorptive hypoglycaemia,
particularly at night. Short-acting and long-acting insulin
analogues have more physiological proﬁles but cannot
yet reproduce those observed in people without dia-
betes.4 A systematic review of clinical trials of insulin ana-
logues involving people with T1DM reported only minor
advantages compared to human insulin.5
Thus, while keeping blood glucose close to normal
can delay or prevent complications, it requires consider-
able personal effort, and may bring with it frequent
periods of hypoglycaemia. The manifestations of hypo-
glycaemia range from the need to ingest quick-acting
carbohydrate to correct mild symptoms, to behaviour
that can be socially aversive, cerebral dysfunction, loss of
consciousness, through to major episodes of coma and
seizure. The inability of MDI therapy to control blood
glucose tightly without an attendant risk of hypogly-
caemia results in many people keeping blood glucose at
higher than clinically recommended levels. A signiﬁcant
proportion go on to develop serious diabetic complica-
tions which reduce both the length and quality of their
lives.1 6 There is therefore an urgent need for better
methods of insulin delivery.
Insulin can also be administered using an infusion
pump (the size of a small mobile phone), which delivers
insulin continuously under the skin via a small plastic
tube and cannula (Continuous subcutaneous insulin
infusion, CSII).7 8 This is not new technology, the ﬁrst
trials took place in the 1970’s, but the devices have since
improved and are now more widely used, particularly in
the USA and some European countries. The devices are
ﬁlled with reservoirs of quick-acting insulin, usually an
insulin analogue 9 and can supply the insulin needed
for both background replacement and to cover meals.
When infused at low rates in between eating, pumps
mimic basal insulin secretion and insulin is generally
delivered more consistently and accurately than is
achievable by long-acting insulin injections. Rapidly
infused insulin boluses, conveniently delivered from the
pump at the push of a button and controlled by the
individual, cover each meal.
Pump therapy is more expensive than MDI, with
pumps costing around £2500–3000 each plus £1500 a
year extra for running costs, mainly consumables. The
marginal cost per annum over MDI was around £1800 in
2007, including both capital and revenue costs.10 The
potential advantages are a more stable blood glucose,
reduced risk of hypoglycaemia, enhanced QoL and a
more ﬂexible lifestyle. Pump treatment may deliver
insulin more effectively than MDI but does not provide
a technological ‘cure’. Indeed, optimal usage still
requires frequent blood glucose monitoring by the user
with careful thought needing to be given to adjustment
of both the background rates—particularly during the
night—and the insulin dose needed at each meal.
It is estimated that only 6% of UK adults with T1DM
use pumps, which is lower than in most comparable
countries.11 In contrast, they may be used by as many as
40% of those with T1DM in the USA.12 Proponents of
pump treatment have proposed that far more people
should be offered this treatment in the UK and have
suggested that current policies are depriving many of
the opportunity to improve glycaemic control, reduce
hypoglycaemia and improve QoL.13
There have been two appraisals of pumps by the UK’s
National Institute for Health and Care Excellence
(NICE), both supported by technology assessment
reports that reviewed the evidence on clinical and cost-
effectiveness. The ﬁrst report14 noted that there were no
trials of pumps against ‘best MDI’ with long-acting and
short-acting analogue insulins; that some trials had
unequal amounts of education in the arms (with more
in the pump arms); and trials had focused on easily
measurable outcomes such as glycosylated haemoglobin
(HbA1c), rather than on beneﬁts such as ﬂexibility of
lifestyle and QoL. The report recommended trials of
pumps against analogue-based MDI. An updated
report10 found that few such trials had been undertaken
—one in children, and three in adults. The three in
adults were small (a total of 103 participants) and had
short follow-up. Furthermore, those participating were
different to those considered suitable for pumps by
NICE, which advises patients use analogue-based MDI
before pump therapy. In 2008, NICE recommended
extending pump treatment to those adults with T1DM
experiencing problems with hypoglycaemia particularly
when this limits their ability to improve glycaemic
control.
Why do REPOSE?
The DAFNE course is a 1-week structured course teach-
ing skills in insulin self-adjustment and carbohydrate
counting,2 currently being delivered in 76 centres across
the UK and Ireland (with over 31 000 individuals having
attended). In many DAFNE centres, reimbursement for
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pump use is conditional on patients having attended a
DAFNE education course and, hence, some people
undertake DAFNE training with the intention of moving
to pump treatment thereafter. It has been our clinical
experience that many such individuals decide not to
switch to pump therapy after attending a DAFNE course,
having realised that what they had actually required was
training in insulin self-adjustment rather than a different
technical way of delivering insulin. Importantly, trials
and observational studies of high-quality training alone
(with MDI), show beneﬁts in blood glucose control,
hypoglycaemia and QoL which are as good if not better
than those reported after pump therapy.2 15 16
One problem with the existing evidence base is that
patients allocated to pumps may have received more
training and attention than those treated using MDI. A
recent observational Italian study17 of pump therapy and
MDI, where both groups received intensive education,
concluded that it might be the education which made
most difference. To our knowledge, no randomised
trials in adults have compared pump treatment with
MDI where the same structured training in insulin
adjustment has been given, so the added beneﬁt of the
pump technology is currently unclear. There is an
urgent need to establish this, and identify the individuals
who are most likely to beneﬁt from using a pump. This
will enable healthcare systems to determine the propor-
tion of adults with T1DM that would beneﬁt from pump
therapy. A randomised controlled trial is needed to
establish these outcomes without bias.
In the UK, NICE has approved the use of pumps in
adults with T1DM with the greatest need, such as inabil-
ity to achieve reasonable control without ‘disabling hypo-
glycaemia’. This is in international terms, a fairly
restricted usage. Evidence on the clinical and cost-
effectiveness of broader availability of pump therapy
relative to MDI is required. Past trials may not be a good
guide; they may have excluded people with persistent
mild-to-moderate hypoglycaemia due to hypoglycaemic
unawareness, who may be those with most to gain.
The aim of REPOSE is to assess whether pump
therapy provides added beneﬁt compared to optimised
MDI therapy, after receiving high-quality structured edu-
cation. We hypothesise that much of the beneﬁt of
pumps may come from the retraining and education in
insulin use given to enable patients to use pumps safely.
The trial builds on pilot work in which a pump course
using DAFNE principles was developed. Recruitment to
REPOSE is now complete and the trial is in follow-up.
METHODS
Study design
REPOSE is a multicentre, parallel group, cluster rando-
mised controlled trial, in which 280 adults with T1DM
were recruited at seven centres across the UK.
Participants were allocated a place on a week-long
DAFNE course. The course groups were then randomly
allocated in pairs to either pump or MDI treatment.
Following the course, participants receive the trial treat-
ment for 2 years, from the secondary care centres they
usually attend. Outcome measures are being collected at
baseline (up to 3 weeks prior to the DAFNE course) and
6, 12 and 24 months postcourse.
A detailed psychosocial study involving both quantita-
tive and qualitative methodology is being undertaken. A
repeated measures, longitudinal questionnaire study is
exploring differences in outcomes between the two trial
arms and the short-term and long-term predictors and
mediators of outcomes. The time-points for follow-up
have been selected to capture both short-term and long-
term post-treatment changes in psychosocial outcomes.
A subsample of 45 participants (25 in the pump arm
and 20 in the MDI arm) took part in repeat qualitative
interviews (post course and at 6 months). The purpose
of these interviews is to aid interpretation of the trial
ﬁndings by identifying, exploring and understanding
any differences and similarities in how participants
manage their diabetes using a pump and MDI treatment
after their courses and over time.
The study also includes a detailed economic analysis
to help guide future recommendations.
Setting
Secondary care centres (three in Scotland, four in
England) with experience both in delivering high-
quality structured education using DAFNE and deliver-
ing pump therapy in adults with T1DM. We identiﬁed
two potential reserve sites in case of difﬁculties with
recruitment, one of which has been activated. Each
centre was asked to recruit 40 participants to 3 pump
and 3 MDI courses (5–8 patients on each course) over
11 months. A list of participating centres can be found
at the end of this paper.
Participants
Inclusion criteria: adults with T1DM for at least
12 months; aged 18 years and above; willing to under-
take intensive insulin therapy with self-monitoring of
blood glucose levels (SMBG), carbohydrate counting
and insulin self-adjustment; who have no preference to
either pump or MDI and are happy to be randomised;
and, who have a need for structured education to opti-
mise diabetes control.
Exclusion criteria: individuals who have already com-
pleted a diabetes education course; have used a pump
in the past 3 years or, have strong clinical indications for
pump therapy in the view of the investigator or, have a
strong desire for pump therapy; renal impairment with a
chance of needing renal replacement therapy within the
next 2 years; uncontrolled hypertension (diastolic blood
pressure >100 mm Hg and/or sustained systolic level
>160 mm Hg); a history of heart disease within the past
3 months; severe needle phobia; a current history of
alcohol or drug abuse; serious or unstable conditions to
preclude safe participation; recurrent skin infections;
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pregnant or planning to become pregnant within the
next 2 years; taken part in any other investigational clin-
ical trial during the 4 months prior to screening; unable
to communicate in English; or, unable to give informed
consent.
Interventions
The standard DAFNE MDI arm
Each course is conducted over ﬁve consecutive days, pro-
viding an average of 38 h of structured education and is
delivered to groups of 5–8 adults aged over 18 years in
an outpatient setting. Courses are delivered by diabetes
specialist nurses and dietitians who have attended an
educator training course, the DAFNE education pro-
gramme, a seven-part programme consisting of 105 h of
structured training.
The DAFNE curriculum uses a progressive modular-
based structure to improve self-management in a variety
of medical and social situations. Content is designed to
deliver key learning topics at the appropriate time during
the week. In this way, knowledge and skills are built up
throughout the course with active participant involve-
ment and problem solving as key methods of learning.
The key modules are: what is diabetes? food and diabetes;
insulin management; management of hypoglycaemia;
sick day rules. Lesson plans give guidance on timing and
a student activity section serves to give an idea of
expected responses. Each meal and snack during the
course is used as an opportunity to practise carbohydrate
estimation and insulin dose adjustment.
MDI participants are using insulin analogues (a quick-
acting insulin analogue and twice daily injections of
insulin detemir, a medium duration analogue).
The DAFNE pump arm
The 5-day structure of the standard adult DAFNE course
has been maintained while modifying the course to
incorporate the additional skills and learning outcomes
of pump therapy. Thus, the principles of insulin dose
adjustment taught on the adult course are maintained.
The additional components of the course have been
tested in a pilot study undertaken prior to the trial. The
need to introduce ‘pump skills’ requires the addition of
a precourse session delivered individually, run 1–2 weeks
before the ‘proper’ DAFNE course.
Pump participants are using a Medtronic Paradigm
Veo insulin pump (Model X54). Short-acting analogue
insulin is being used, since in a meta-analysis9 this has
been shown to lower HbA1c to a greater extent than
traditional soluble insulin.
Fidelity testing of pump courses was undertaken in
order to assess whether courses were delivered according
to DAFNE philosophy and principles and that the edu-
cators had the necessary skills to deliver these principles.
Standard DAFNE courses were not tested as there is a
rigorous quality assurance programme of MDI courses
in standard care.
All participants in both groups are invited to an add-
itional DAFNE follow-up group session at 6 weeks post
course, which is standard for DAFNE course attendees.
The insulin pumps include a Medtronic Bolus Wizard,
to aid calculation of insulin doses. To reduce any potential
bias, MDI participants are also given access to a bolus cal-
culator (Accu-Chek Aviva Expert Bolus Advisor System).
The duration of any additional diabetes-related
contact is recorded throughout the trial.
Participants receive the allocated treatment for
2 years. Treatment may be changed at the discretion of
the local principal investigator if self-management of dia-
betes has become ineffective and is considered a risk to
the individual. If the participant fails to attend the
pump course they are withdrawn from pump treatment.
Outcomes
Primary outcomes
▸ The main primary outcome will be the change in
HbA1c after 2 years in those participants whose base-
line HbA1c was at or above 7.5% (58 mmol/mol).
▸ The key secondary end point will be the proportion
of participants reaching the NICE target of a HbA1c
level of 7.5% (58 mmol/mol) or less after 2 years (of
all participants).
HbA1c is the accepted gold-standard measure of glycaemic
control. This will provide both a measure of efﬁcacy, and a
means for modelling long-term cost-effectiveness.
However, it is important to note that HbA1c may not fall in
patients who enter the trial with low baseline levels of
HbA1c, but who might be experiencing frequent hypogly-
caemia, or wish to increase dietary freedom. Success for
such individuals would be an HbA1c level which is main-
tained or even rises slightly with a reduction in the fre-
quency of hypoglycaemia. We are including such patients
since they can provide important information about QoL
and the potential of pump therapy to reduce rates of hypo-
glycaemia. Since their glycaemic control may not alter,
including their HbA1c data would reduce our statistical
power to establish improvement in our primary end point.
We are therefore powering the trial on the number of par-
ticipants with a baseline HbA1c above or equal to 7.5%
(58 mmol/mol) and in whom a fall would reﬂect worth-
while improvements in glycaemic control.
Since HbA1c can be measured using different techni-
ques, we are ensuring standardisation by testing in a
central laboratory, as well as in a local lab. We are also
conducting a substudy, to determine the variation
between central and local results. This will, in part,
inform a decision as to the acceptability of using local
lab values where central values are missing.
Secondary outcomes
Biomedical outcomes
The following outcomes are being measured at 6, 12
and 24 months:
▸ Episodes of moderate and severe hypoglycaemia (count).
▸ Insulin dose (units/kg body weight).
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▸ Body weight (kg).
▸ Lipids (high-density lipoprotein (HDL) cholesterol,
total cholesterol).
▸ Proteinuria (albumin creatinine ratio—a sensitive
measure of proteinuria).
Hypoglycaemia: We are recording episodes of both
severe and moderate hypoglycaemia and speciﬁcally
recording episodes at night (those occurring between
23:00 and 7:00). We are using a standard deﬁnition of
severe episodes (an episode leading to cognitive impair-
ment sufﬁcient to cause either coma or requiring the
assistance of another person to recover).18 19 The
number of severe episodes are reliably recorded by
patients for up to 1 year.20 Pumps have been shown to
reduce hypoglycaemia in some studies but since DAFNE
and similar educational interventions are also associated
with falls in severe episodes21 22 we may have insufﬁcient
power to detect a difference between the two groups.
During the last NICE appraisal of pump therapy, the
question of the impact of moderate hypoglycaemia was
raised. The modelling had included only severe hypogly-
caemia, and the point was made that moderate hypogly-
caemia, sufﬁcient to interrupt activities of daily living,
might, because of greater frequency, have more cumula-
tive effect on QoL than severe hypoglycaemia. We are
therefore also recording rates of moderate hypogly-
caemia in an attempt to increase power and identify the
ability of pumps to reduce rates of hypoglycaemia. We
deﬁne moderate hypoglycaemia as ‘any episodes which
could be treated by that individual, but where hypogly-
caemia caused signiﬁcant interruption of current activity,
such as having caused impaired performance or embar-
rassment or having been woken during nocturnal sleep’.
Since these episodes are more frequent, reliable recall
of such events is unlikely to be sustained for more than
a few weeks. We therefore ask participants to record the
number and timing of moderate episodes over the
4 weeks prior to each follow-up visit. We used this
approach successfully to record the frequency of mild
episodes in a recent epidemiological study of hypogly-
caemic burden in diabetes.18
We will assess the impact of both, by comparing QoL
in those with only moderate hypoglycaemia, versus those
with moderate and severe.
Insulin dose and body weight: pump treatment may
result in the use of less insulin leading to a favourable
effect on body weight. We record total insulin dose at
each time point and calculate units/kg body weight.
Lipids and proteinuria (as measured by albumin cre-
atinine ratio): A recent study23 reported little difference
in HbA1c on pump therapy compared to MDI but
found less progression to microalbuminuria in the
pump group, and also lower cholesterol levels.
Safety outcomes
Diabetic ketoacidosis is being recorded through the
assessment of serious adverse events at any point in time
during the trial.
Quantitative psychosocial outcomes
The following are being measured using a participant
self-completed questionnaire administered at 6, 12 and
24 months:
▸ QoL (both generic and diabetes speciﬁc)
▸ Fear of hypoglycaemia
▸ Treatment satisfaction
▸ Emotional well-being
There has been limited examination of the impact of
pump therapy on these areas, on how and why these may
change over time and why individuals are able or unable
to use pump therapy to improve glycaemic control. Rubin
and Peyrot24 reviewed the evidence on ‘patient reported
outcomes’ and concluded that at present, there is little evi-
dence that pump therapy improved them.
QoL: Diabetes-speciﬁc QoL is being assessed using the
scale (DSQOLS), a reliable and valid measure.25
Speciﬁcally designed for the German study on which UK
DAFNE is based, it is included to facilitate important
comparisons between the UK and German studies. In
addition, generic measures of QoL, the WHO QoL
Abbreviated Questionnaire (WHOQOLBREF)26 and
functional health status using the Short Form Health
Survey (SF-12)27 and EuroQoL (EQ5D)28 are being
used. The SF-12 will facilitate comparison with ‘healthy
controls’ and other long-term conditions. The SF-12 and
EQ5D will also be used by the health economists to
derive health economic data.
Fear of hypoglycaemia: The Hypoglycaemia Fear
Survey29 is a well validated psychometric tool assessing
participants’ fear of hypoglycaemia both overall and sep-
arately for behaviour and worry. A speciﬁc beneﬁt to the
survey is that it may be able to identify participants who
are likely to maintain high-blood glucose levels, thus
aiding understanding of potential reasons for poor gly-
caemic control. A study by Nixon and Pickup30 in
people who had been using a pump for an average of
5 years, found that fear of hypos remained a problem.
Treatment satisfaction: The Diabetes Treatment
Satisfaction Questionnaire31 has proven to be highly sen-
sitive in clinical trials.32 Treatment satisfaction refers to
an individual’s subjective appraisal of their experience
of treatment, including ease of use, side effects and efﬁ-
cacy. Improvements in satisfaction are not necessarily
accompanied by improvements in QoL; treatment satis-
faction can be high despite diabetes having a negative
impact on QoL, which is why it is important to measure
both separately.
Emotional well-being: The Hospital Anxiety and
Depression Scale33 measures anxiety on one subscale
and depression on another through the use of seven
questions for each characteristic. It is important to
measure emotional well-being in the trial as participants
may ﬁnd it easier to manage their condition after
DAFNE education or with one of the treatments. This
might have a substantial effect on their emotional well-
being that the QoL measures are not sensitive enough
to pick up.
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Qualitative substudy
Participant interviews conducted within 2 weeks of
course completion explored:
▸ Experiences of diabetes management prior to the trial.
▸ Understandings of the trial, experiences of recruit-
ment and motivation for participation.
▸ Reactions to, and views about, randomisation
outcome.
▸ Expectations and concerns about trial participation
and (if relevant) change to pump therapy.
▸ Experience of and views about their course and (if
relevant) change to pump therapy.
▸ Likes/dislikes of pump or MDI treatment.
▸ Changes made to diabetes management since the
course and any short-term/long-term goals set.
Follow-up interviews at 6 months were used to explore:
▸ Continuities and changes in how participants
managed their diabetes since their last interview and
the reasons for these.
▸ Barriers and facilitators to sustaining intensive insulin
therapy using a pump or MDI treatment.
▸ Reasons for pump discontinuation and/or treatment
non-adherence.
▸ Any changes in participants’ perceptions and atti-
tudes towards their disease and the reasons for these
changes.
In order to contextualise and interpret participants’
responses, additional issues and areas were also explored
in their baseline and 6-month interviews. These
included: participants’ work and family commitments;
support received from family and friends; their contact
with diabetes health professionals within and without
the trial; their views about the information, support and
clinical care received; and, any unmet needs for infor-
mation and support.
Health economics
We will undertake a health economic evaluation to
address the question ‘What is the cost effectiveness of
pump therapy compared to MDI in patients receiving the
DAFNE structured education programme?’ We will
undertake both a within trial and a modelled patient life-
time analysis, the latter being the primary focus of the
evaluation. The following outcomes will be measured.
▸ Quality adjusted life years (QALYs) for intervention
and comparator modelled over a lifetime horizon.
▸ Total costs of intervention and comparator over a life-
time horizon, accounting for the costs of complica-
tions and adverse events as well as initial intervention
costs.
▸ QALYs observed over 2-year trial period in each trial
arm.
▸ Cost of each trial arm over 2 years
▸ Incremental cost-effectiveness ratios (ICERs) over a
lifetime horizon and over the 2-year trial period
▸ Uncertainty surrounding the ICERs (cost-effectiveness
plane, cost-effectiveness acceptability curve and fron-
tier, probability of cost-effectiveness at willingness-to-pay
thresholds of £20 000 and £30 000 per QALY, determin-
istic sensitivity analyses).
The within-trial analysis will be conducted in line with
Ramsey et al’s34 recommendations for cost-effectiveness
analysis alongside clinical trials. Speciﬁcally, the analysis
will use unit costs consistent with measured resource use,
use EQ-5D as the measure of health outcome, and follow
the guiding principles outlined for the analysis of eco-
nomic measures. The baseline analysis will be based on
complete cases, with an additional sensitivity analysis
using multiple imputation to account for missing data
using the ICER procedure within STATA. Patient-level
data is being collected for equipment, drugs and NHS
contacts. Unit costs will be taken from standard sources
(NHS Reference Costs, British National Formulary,
PSSRU), plus a survey of pump costs across the recruiting
centres. Utility scores for each patient will be calculated
using the UK EQ-5D. QALYs for each patient will be esti-
mated by calculating the area under the curve deﬁned by
EQ-5D utility score, mortality and length of follow-up.
The long-term modelling analysis will use the
Shefﬁeld Type 1 Diabetes Policy model—which has been
developed as part of the national DAFNE Research
Programme—in combination with data from the trial.35
It will be conducted in line with the NICE reference
case for economic evaluations (NIHR, 2008) and the
Guidelines for computer modelling of diabetes and its
complications.36 The model covers the entire T1DM
care pathway including initiation, management, out-
comes and long-term complications. The analysis will
include overall cost-effectiveness, analysis of subgroups
and use methods of probabilistic sensitivity analysis to
quantify remaining uncertainties in costs and beneﬁts.
Sample size
It is generally accepted that a difference of 0.5%
(5.5 mmol/mol) in HbA1c is clinically worthwhile. To
detect this difference with a SD of 1% at 80% power and
5% two-sided signiﬁcance using a t test requires 64
patients per group for participants over 7.5% HbA1c. To
allow for a clustering effect of the educators, with an
average of seven patients per DAFNE group and a
within-course intraclass correlation coefﬁcient (ICC) of
0.05, which is common in diabetes care, the sample size
increases to 84. Allowing also for a 10% drop out, the
sample size per group becomes 93. Audit of the DAFNE
database shows that 75% of participants have an HbA1c
of over 7.5%, so overall we require 124 participants per
group, that is, 248 in total. We planned to recruit 280
participants which increases the power to 85% but
which allows for some variation in drop-out rates and
the proportion of patients with HbA1c >7.5%. However,
our ﬁnal recruitment was 321.
Assignment to control and intervention
Informed consent was obtained by the principal investi-
gator or educator, trained in good clinical practice. After
consent, participants were allocated to a REPOSE
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DAFNE course, depending on the participants’ availabil-
ity. Courses were randomised in pairs, stratiﬁed by
centre, to either DAFNE + pump or DAFNE + MDI, by a
statistician using a computerised system within Shefﬁeld
Clinical Trials Research Unit (CTRU). The ﬁnal pair of
courses at each centre were randomised using minimisa-
tion, based on the participants’ most recent available
HbA1c result (HbA1c >or equal to 7.5% vs <7.5%).
Data collection and management
A case report form (CRF) is completed by the educator
at each study visit, with the participant present. A psy-
chosocial questionnaire pack is self-completed by the
participant prior to the visit in order to reduce potential
reporting bias. CRF data is entered at local centres by
educators/administrators onto a centralised online data-
base managed by Shefﬁeld CTRU. Participant com-
pleted questionnaires are posted to Shefﬁeld CTRU and
entered centrally by Shefﬁeld CTRU administrators.
Data is stored in accordance with Shefﬁeld CTRU stand-
ard operating procedures.
Data quality is being checked using a combination of
point of entry validation, 10% veriﬁcation of data entry,
postentry validation and other ad hoc validation by the
trial monitoring committees and CTRU statisticians. A
copy of the data management plan will be provided on
request.
Statistical analysis
The primary analysis will be a linear model of HbA1c at
2 years with treatment (pump/MDI), centre and base-
line HbA1c as ﬁxed effect covariates and course as a
random intercept. The analysis will be undertaken using
generalised estimating equations (GEE). We plan to use
Poisson regression on the number of moderate or severe
hypoglycaemic episodes in 2 years with the same covari-
ates, again using a GEE approach to account for cluster-
ing; however, we will test the adequacy of Poisson
regression against alternatives such as the negative-
binomial and zero-inﬂated Poisson regressions. We will
use an intention-to-treat analysis, but will explore the
effect of switching by conducting a per protocol second-
ary analysis. Participants who dropped out before receiv-
ing the intervention were substituted where possible, to
ensure the courses were run with adequate numbers of
participants, but these individuals will not form part of
the analysis set. A copy of the statistical analysis plan will
be provided on request.
Monitoring
Three committees were established to govern the
conduct of this study: an independent Trial Steering
Committee (TSC) and Data Monitoring and Ethics
Committee (DMEC) and day to day running by an
internal Trial Management Group (TMG). The compos-
ition of the TSC and DMEC are listed at the end of this
paper. These committees function in accordance with
Shefﬁeld CTRU standard operating procedures.
Emerging evidence is being monitored through;
▸ 6-monthly updating searches.
▸ Auto-alerts set up in Medline.
▸ General surveillance by project team, for example at
diabetes conferences.
▸ Feedback from members of the TSC.
The study is classed as a low-risk clinical trial of an
investigational medicinal product (CTIMP) by the
Medicines and Healthcare Regulatory Authority
(MHRA) and we adhere to the reporting requirements
considered appropriate for such trials. Details of any
adverse events are collected at each follow-up time
point. Participants are also encouraged to contact their
local diabetes team if they experience any adverse
health events. Serious adverse events are assessed by the
local principal investigator and reported to Shefﬁeld
CTRU within 24 h, in accordance with Shefﬁeld CTRU
standard operating procedures. Adverse events are
reviewed by the three study oversight committees.
On site monitoring of sites is being undertaken
before, during and after the trial, with a minimum of
three visits at each site, undertaken by the trial monitor.
Ethical considerations
Risks
Intensive insulin regimens are commonly used in this
age group, and it is difﬁcult to envisage signiﬁcant add-
itional risks from participation in this study. Early experi-
ence using pump therapy documented increased risk
of diabetic ketoacidosis but this has not been substan-
tiated in more recent trials and should be largely pre-
ventable by appropriate sick day rules training, a
standard part of the DAFNE curriculum. There is a
small risk of cannula site infection with insulin infusion
but this is minimised by proper instruction in site care
and regular change of site. Some forms of intensiﬁed
insulin therapy are reported to increase severe hypogly-
caemia risk but in the parent programme for DAFNE
and more recently in a clinical DAFNE audit, we have
shown a reduction in severe hypoglycaemia rate and dia-
betic ketoacidosis at 1 year after DAFNE training.21 22
Anticipated benefits
Both courses aimed to provide adults with the skills to
closely match their insulin dose to their food choice and
regularly correct their blood sugar. The anticipated ben-
eﬁts are therefore improved blood glucose control, QoL
and self-efﬁcacy.
Patient recruitment
All participants received patient information literature
describing the anticipated risks and beneﬁts of taking
part and had the opportunity to ask questions prior to
giving informed consent.
Other ethical issues regarding study participation
All blood samples and biomedical measurements are
routinely taken in clinic. Blood glucose is measured at
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home by a meter from blood taken by ﬁnger prick sam-
pling (SMBG), which people with diabetes perform
several times each day.
No new drugs or insulins are being used. All are
licensed and currently in use in the UK with this age
group. Intensive insulin regimens are currently being
used in many UK centres, with some starting this
regimen from the time of diagnosis.
Individuals who participate are fully aware that they
are not guaranteed the use of the pump either during
or at the end of the study. However, those pump partici-
pants who express a preference to continue therapy and
have measurable evidence of beneﬁt (HbA1c reduction
greater than 0.5%; reduction in hypoglycaemia rate;
documentable improvement in a QoL outcome) will be
supported by their diabetes team in seeking local NHS
approval for continuation of pump therapy. Participants
reverting to MDI will be reassessed at 4–6 months; if
their QoL or HbA1c or hypoglycaemia status has dete-
riorated on MDI, a direct approach to the local commis-
sioners or health board for conversion to pump therapy
will be made.
Participants are free to withdraw from the study at any
time. Those who wish to switch back to MDI are seen by
one of the centre DAFNE educators who work with
them to ensure they have the necessary information to
use their DAFNE skills with multiple injections.
Service users
As part of the DAFNE NIHR programme grant, 15
DAFNE graduates were recruited to act as a ‘user group’
and contribute to different aspects of the work. The
group agreed to serve on steering groups providing
opinion and assistance in reﬁning research projects. We
invited two members to join both the steering group
and other investigator meetings. One of the project
group is a pump user.
Dissemination
We shall disseminate ﬁndings to study participants and
through peer reviewed publications and conference pre-
sentations, including presentations to lay user groups.
Trial updates will be provided on the study website.
DISCUSSION
Progress so far (June 2014)
Recruitment is now closed at all participating centres
and follow-up is ongoing. A total of 321 participants
were recruited and 46 DAFNE courses administered,
more than the original target of 280 participants and 42
DAFNE courses. The targets were increased to counter a
higher than expected number of withdrawals prior to
the DAFNE courses. We had anticipated the potential
for recruitment problems and so had recruited a reserve
centre which was introduced to facilitate a pair of
courses, while an existing centre recruited to a seventh
and eighth course. We plan to complete follow-up in
July 2015 and report results in early 2016.
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